Oncopeptides Q1 2024: Progress in Spain - Redeye

Redeye comments on Oncopeptides' Q1 report, which had few surprises in terms of financials. Commercial progress has been made with a successfully negotiated price and reimbursement in Spain, which will be an important market in reaching overall profitability.

Länk till analysen i sin helhet: https://www.redeye.se/research/1013841/oncopeptides-q1-2024-progress-in-spain?utm_source=finwire&utm_medium=RSS